Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.

June 15, 2020June 17, 2020

Galapagos, e-therapeutics Partner to Identify Compounds to Treat Fibrotic Diseases

News

Galapagos and e-therapeutics are partnering to investigate mechanisms involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions and to select potential therapeutic candidates. The collaboration will combine Galapagos’ ... Read more

June 2, 2020June 2, 2020

CHMP Favors EU Approval of Ofev for Progressive Fibrosing ILDs

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Ofev (nintedanib) for the treatment of progressive fibrosing interstitial lung diseases (ILDs). ... Read more

May 26, 2020May 26, 2020

Ofev Approved in US and Canada for Progressive Fibrosing ILDs

News

Ofev (nintedanib), an oral medication by Boehringer Ingelheim, is now approved to treat people with progressive fibrosing interstitial lung diseases (ILDs) in the U.S. and Canada. These approvals, by the ... Read more

May 11, 2020May 11, 2020

Algernon Gets Nod to Launch Phase 2 IPF Trial of NP-120 in Australia

News

Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120 (ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and associated chronic cough. Royal ... Read more

April 27, 2020April 27, 2020

Veracyte Acquires Rights to Blood Sample Gene Test of Likely IPF Outcomes

News

Veracyte has acquired the rights to a gene signature that may serve as a tool, based on a simple blood sample, for determining likely disease outcomes for people with idiopathic ... Read more

April 17, 2020April 17, 2020

Risk of Death High for IPF Patients Soon After Acute Flare, Study Says

News

People with idiopathic pulmonary fibrosis (IPF) have shorter survival times after an acute exacerbation than do those with other interstitial lung diseases (ILD), often dying within a few months of such ... Read more

April 10, 2020April 10, 2020

Tuberculosis May Cause Spontaneous Tumor Regression in IPF Patients with Lung Cancer, Case Report Suggests

News

In very rare cases, a tuberculosis infection in people with idiopathic pulmonary fibrosis (IPF) and lung cancer may help activate the immune system and induce a spontaneous cancer remission, a ... Read more

August 15, 2016August 17, 2016

Newly Found Genetic Mutation Seen to Increase Risk of Pulmonary Fibrosis

News

Researchers at Johns Hopkins University have identified a new gene that, when mutated, increases the risk for pulmonary fibrosis and emphysema by reducing the activity of telomerase, the enzyme ... Read more

August 11, 2016August 11, 2016

Software Detects ‘Molecular Signatures’ in Development of Lung and Liver Fibrosis

News

A collaborative research effort identified new pathways involved in fibrosis using a software tool known as “Regeneration Intelligence,” which evaluated perturbations in several signaling pathways in lung and liver fibrosis, and in glaucoma. ... Read more

August 2, 2016April 12, 2017

Esbriet Found to Reduce Idiopathic Pulmonary Fibrosis Progression Across Disease Stages

Esbriet, News

Patients with idiopathic pulmonary fibrosis (IPF) may benefit from Esbriet (pirfenidone) treatment regardless of their disease stage and baseline lung function, according to a study by researchers at the University ... Read more